PCI Pharma Services (PCI) has installed and validated new serialization system at its manufacturing Center of Excellence in Tredegar, UK.
The investment in new system is a part of PCI’s continued effort to expand its serialization capabilities to support clients in advance of implementation dates for the European Falsified Medicines Directive (EU FMD).
Additionally, the new system allows the firm to increase supply for the US and emerging markets, including countries such as China, Turkey, Brazil, Saudi Arabia and others.
The serialization system is designed to meet all EU member country requirements for serialization and specialized labeling, including application and integration of advanced anti-counterfeiting technologies.
PCI Tredegar operations director Jim Neville said: “This is an important addition to the site’s capabilities.
“Being able to offer this fully flexible service and work in partnership with our customers to deliver a trusted, seamless service is critical, and being ahead of the timelines with this offering ensures compliance with the EU FMD.”
The new system, which is said to be highly flexible, is designed to deliver machine and human-readable coding, tamper evident solutions and Bollini labeling, which is linked to a case loading and aggregation station. The final aggregation station connects cases to pallet.
PCI said in a statement: “PCI is a strong supporter of the advanced use of aggregation to support product security, realizing the significant benefits in packaging operations, as well as the broader pharmaceutical supply chain.”
The firm said that the investment in the new Serialization system at the Tredegar facility is part of its pan to develop the Serialization services across its global network. This brings the total number of lines being operated by the company to more than 90.
PCI is a provider of outsourced services across the entire pharmaceutical supply chain, including drug development and manufacturing, clinical trials and packaging services to the pharmaceutical industry.